Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Korea Joongang Daily on MSN14h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development ...
BioSpace1d
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...
Avacta Appoints Brian Hahn as Chief Financial Officer
LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful ...
Frontiers2d
Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies
Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...
precisionmedicineonline5d
Biocytogen Partners With Acepodia to Develop Dual-Payload Bispecific Antibody
The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced ...